Exelixis, Inc. - Product Pipeline Review - H2 2011

Global Markets Direct, November 2011, Pages: 134

Exelixis, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Exelixis, Inc. - Product Pipeline Review - H2 2011” provides data on the Exelixis, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Exelixis, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Exelixis, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Exelixis, Inc. - Brief Exelixis, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Exelixis, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Exelixis, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Exelixis, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Exelixis, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Exelixis, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Exelixis, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Exelixis, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Exelixis, Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Exelixis, Inc.; Exelixis, Inc. - Key Therapeutics; Exelixis, Inc. - Pipeline Overview and Promising Molecules; Exelixis, Inc. - News; Exelixis, Inc. - Latest Updates; Exelixis, Inc. - Pipeline; Exelixis, Inc. - Discontinued/Dormant Projects

List of Tables
List of Figures
Exelixis, Inc. Snapshot
Exelixis, Inc. Overview
Key Information
Key Facts
Exelixis, Inc. – Research and Development Overview
Key Therapeutic Areas
Exelixis, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Exelixis, Inc. – Pipeline Products Glance
Exelixis, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Exelixis, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Exelixis, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Exelixis, Inc. – Drug Profiles
BMS-908662 + Pepcid
Product Description
Mechanism of Action
R&D Progress
Cabozantinib
Product Description
Mechanism of Action
R&D Progress
S1P1R Agonist
Product Description
Mechanism of Action
R&D Progress
XL184 + Erlotinib
Product Description
Mechanism of Action
R&D Progress
XL184 + Rosiglitazone
Product Description
Mechanism of Action
R&D Progress
XL184 + Temodar + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
XL499
Product Description
Mechanism of Action
R&D Progress
XL541
Product Description
Mechanism of Action
R&D Progress
XL647
Product Description
Mechanism of Action
R&D Progress
XL652/XL014
Product Description
Mechanism of Action
R&D Progress
XL888
Product Description
Mechanism of Action
R&D Progress
Exelixis, Inc. – Pipeline Analysis
Exelixis, Inc. – Pipeline Products by Therapeutic Class
Exelixis, Inc. - Pipeline Products By Target
Exelixis, Inc. – Pipeline Products by Route of Administration
Exelixis, Inc. – Pipeline Products by Molecule Type
Exelixis, Inc. – Recent Pipeline Updates
Exelixis, Inc. - Dormant Projects
Exelixis, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
XL019
XL228
XL418
XL647 + XL147
XL820
XL844
XL844 + gemcitabine
Exelixis, Inc. – Company Statement
Exelixis, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Oct 31, 2011: Exelixis To Initiate Cabozantinib '306 Trial With Pain Endpoint In Metastatic Castration-resistant Prostate Cancer
Aug 31, 2006: Exelixis Files IND Application For XL228
May 31, 2011: Exelixis Announces Cabozantinib Data Presentations At 2011 ASCO Annual Meeting
May 31, 2009: Exelixis And BMS Presents Phase II Data At ASCO For XL184
Sep 30, 2004: Exelixis Releases Pre-Clinical Data On Two Spectrum Selective Kinase Inhibitors In Development - XL647 And XL999 - At EORTC
May 30, 2009: Exelixis Reports Encouraging Phase I Data For XL228
May 30, 2007: Exelixis Initiates Phase II Trial Of XL647 In NSCLC Patients Who Have Previously Benefited From EGFR Inhibitors Or Have The T790M Mutant Form Of EGFR
Jan 30, 2007: Exelixis Files IND Application for XL418
Nov 29, 2007: Exelixis To Receive Milestone Payment From Bristol-Myers Squibb For Achievement Of Liver X Receptor Agonist Development Milestone
Oct 28, 2008: Exelixis Reports Encouraging Phase I Data For XL184 At EORTC-NCI-AACR Symposium
Jul 28, 2008: Exelixis Notifies GlaxoSmithKline Of Proof-of-Concept For XL184
Jul 25, 2005: Exelixis Initiates Phase I Clinical Trial For Anticancer Compound XL820
Apr 25, 2005: Exelixis Files IND Application For Novel Anticancer Compound XL820
Oct 24, 2011: Exelixis's Cabozantinib Meets Primary Endpoint In Phase III Clincial Trial For Medullary Thyroid Cancer
Oct 24, 2007: Exelixis Reports XL647 Clinical Data At AACR-NCI-EORTC Conference
May 24, 2007: Exelixis Files IND Application For XL019, A Novel Anticancer Compound Targeting The JAK/STAT Signaling Pathway
Oct 23, 2009: Exelixis And Bristol-Myers Squibb Reports New Phase II Data For XL184
Oct 23, 2008: Exelixis Reports Positive Phase 1 Data For XL228 at EORTC-NCI-AACR Symposium
Oct 23, 2007: Updated Phase I Data For Exelixis' XL184 Demonstrate Pharmacodynamic And Clinical Anti-Tumor Activity
May 23, 2011: Exelixis Announces Publication Of Phase I Clinical Trial Of Cabozantinib In Journal Of Clinical Oncology
Jul 21, 2008: Exelixis Initiates Phase III Trial Of XL184 In Medullary Thyroid Cancer
Jun 20, 2010: Bristol Returns Cancer Drug XL184 To Exelixis
May 20, 2010: Exelixis Reports Encouraging Interim Data From Ongoing Adaptive Randomized Discontinuation Trial Of XL184 In Solid Tumors
May 20, 2010: Exelixis Reports Long-Term Phase I Results Of XL184 In Cohort Of Medullary Thyroid Cancer Patients
Feb 19, 2004: Exelixis Files IND Application For Anticancer Agent XL647
Nov 18, 2010: Exelixis Reports Promising Phase II Interim Data Of XL184 In Ovarian Cancer
Nov 18, 2010: Exelixis Reports Promising Phase II Interim Data Of XL184 In Patients With Castration-Resistant Prostate Cancer
Nov 18, 2009: Exelixis Reports Encouraging Phase I Data For XL147 In Combination With Erlotinib
Feb 17, 2011: Exelixis's Cabozantinib Phase II Data Demonstrate Encouraging Clinical Activity In Patients With Castration-Resistant Prostate Cancer
Jun 16, 2008: Exelixis Reaches Agreement With FDA On Special Protocol Assessment For XL184 Phase III Trial
Nov 15, 2005: Data From Phase I Trial Of Exelixis XL647 Presented At Cancer Conference
Jun 13, 2008: Exelixis Presents Clinical Data Supporting The Safety And Initial Clinical Activity Of XL228 In Chronic And Acute Leukemia
Dec 10, 2007: Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor Of JAK2
Oct 10, 2008: Exelixis Reports Positive Phase 1 Data For XL228 At EORTC-NCI-AACR Symposium
Jan 10, 2011: Exelixis Receives FDA Orphan Drug Designation For Thyroid Cancer Drug
Nov 09, 2006: Exelixis Presents Preliminary Phase I Results Of XL184
Nov 09, 2006: Exelixis Reports Additional Data From A Phase I Trial Of XL647 In Patients With Advanced Solid Tumors
Dec 08, 2008: Exelixis Reports Positive Phase 1 Data For XL228 At ASH Annual Meeting
Nov 08, 2006: Phase I Data For Exelixis' Kit Inhibitor XL820 Presents At EORTC
Sep 07, 2011: Exelixis Reaches Pre-Specified Number Of Events For Final Data Analysis In EXAM Trial
Jan 07, 2008: Exelixis Initiates Phase I/II Trial Of XL184 In Patients With Non-Small Cell Lung Cancer
Dec 06, 2005: Exelixis And Bristol-Myers Squibb Signs New Collaboration Agreement To Develop Novel Cardiovascular Disease Treatments
Jul 06, 2011: Exelixis Provides Update On Ongoing Phase III Pivotal Trial Of Cabozantinib
Jun 06, 2011: Exelixis's Cabozantinib Phase II Data Demonstrate Encouraging Clinical Activity In Patients With Metastatic Castration-Resistant Prostate Cancer
Jun 05, 2011: Exelixis' Cabozantinib Demonstrates Broad Clinical Activity In Multiple Tumor Types
Sep 04, 2007: Exelixis Reports Encouraging Interim Data From A Phase 2 Trial Of XL647 As First-Line Therapy For Non-Small Cell Lung Cancer
Jun 04, 2011: Exelixis's Cabozantinib Demonstrates Encouraging Clinical Activity In Patients With Metastatic Ovarian Cancer
Jun 03, 2006: Encouraging Phase I Trial Results For XL647 In Patients With Advanced Solid Malignancies Presented At ASCO
Jun 03, 2004: Exelixis Initiates Phase 1 Trial For Anticancer Compound XL647
Oct 02, 2008: Exelixis Files IND Application For XL888
Sep 02, 2011: Exelixis To Provide Update On Cabozantinib At Stifel Nicolaus Healthcare Conference
Jun 02, 2008: Exelixis Reports Phase 1 And Phase 2 Data For XL647 At ASCO
May 02, 2005: Exelixis Files IND Application for Novel Anticancer Compound XL844
Aug 01, 2007: Exelixis Initiates Phase II Clinical Development Program For XL647 In Patients With Metastatic Non-Small Cell Lung Cancer
Jun 01, 2008: Exelixis Reports Encouraging Phase 1 Data For XL184 At ASCO
Financial Deals Landscape
Exelixis, Inc., Deals Summary
Exelixis, Inc., Pharmaceuticals & Healthcare, Deal Details
Partnerships
Exelixis Enters Into Collaboration With Bristol-Myers Squibb
Exelixis Enters Into Co-Development Agreement With Boehringer Ingelheim
Bristol-Myers Squibb Enters Into Collaboration Agreement With Exelixis
Exelixis Enters Into Collaboration Agreement With Bristol-Myers Squibb
Exelixis Enters Into Agreement With Bristol-Myers Squibb For XL413
Exelixis Extends Research Collaboration Agreement With Bristol-Myers Squibb
Exelixis Enters Into Co-Development Agreement With Genentech
Exelixis Enters Into Co-Development Agreement With Bristol-Myers Squibb For XL139
Exelixis Extends Research Collaboration With Bristol-Myers Squibb
Exelixis Enters Into Co-Development Agreement With Genentech
Exelixis Enters Into Collaboration Agreement With Bristol-Myers Squibb
Exelixis Enters Into Co-Development Agreement With Sankyo
Exelixis Enters Into Collaboration Agreement With Bristol-Myers Squibb
Exelixis Enters Into Co-Development Agreement With Genentech
Exelixis Amends Its Collaboration Agreement With GlaxoSmithKline
Licensing Agreements
Ligand Pharmaceuticals Amends Licensing Agreement With Exelixis
Exelixis Enters Into Licensing Agreement With Washington State University
Exelixis Enters Into Licensing Agreement With Bristol-Myers Squibb For XL475
Sanofi-Aventis Enters Into Licensing And Collaboration Agreement With Exelixis
Bristol-Myers Squibb Enters Into Licensing Agreement With Exelixis
Exelixis Enters Into Licensing Agreement With GlaxoSmithKline For XL880
Exelixis Enters Into Licensing Agreement With Wyeth Pharmaceuticals
Exelixis Enters Into Licensing Agreement With Symphony Evolution
Exelixis Enters Into Licensing Agreement With Helsinn Healthcare For XL119
GeneGo Enters Into Licensing Agreement With Exelixis
Equity Offering
Exelixis Completes An Underwritten Public Offering For $190 Million
Exelixis Completes Public Offering Of $72 Million
Exelixis Completes Public Offering Of $97 Million
Exelixis Completes Public Offering Of $50 Million
Debt Offering
Exelixis Completes Private Placement Of Senior Secured Notes For $80 Million
Acquisition
Taconic Farms Acquires Stake In Artemis From Exelixis
Exelixis Acquires X-Ceptor Therapeutics
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Exelixis, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Exelixis, Inc. – Pipeline by Stage of Development, H2 2011
Exelixis, Inc. – Phase III, H2 2011
Exelixis, Inc. - Phase II, H2 2011
Exelixis, Inc. - Phase I, H2 2011
Exelixis, Inc. - Pipeline By Therapeutic Class, H2 2011
Exelixis, Inc. - Pipeline By Target, H2 2011
Exelixis, Inc. – Pipeline By Route of Administration, H2 2011
Exelixis, Inc. – Pipeline By Molecule Type, H2 2011
Exelixis, Inc. – Recent Pipeline Updates, H2 2011
Exelixis, Inc. - Dormant Developmental Projects, 2010
Exelixis, Inc. - Discontinued Pipeline Products, 2010
Exelixis, Inc., Other Locations
Exelixis, Inc., Deals Summary
Exelixis Enters Into Collaboration With Bristol-Myers Squibb
Exelixis Enters Into Co-Development Agreement With Boehringer Ingelheim
Bristol-Myers Squibb Enters Into Collaboration Agreement With Exelixis
Exelixis Enters Into Collaboration Agreement With Bristol-Myers Squibb
Exelixis Enters Into Agreement With Bristol-Myers Squibb For XL413
Exelixis Extends Research Collaboration Agreement With Bristol-Myers Squibb
Exelixis Enters Into Co-Development Agreement With Genentech
Exelixis Enters Into Co-Development Agreement With Bristol-Myers Squibb For XL139
Exelixis Extends Research Collaboration With Bristol-Myers Squibb
Exelixis Enters Into Co-Development Agreement With Genentech
Exelixis Enters Into Collaboration Agreement With Bristol-Myers Squibb
Exelixis Enters Into Co-Development Agreement With Sankyo
Exelixis Enters Into Collaboration Agreement With Bristol-Myers Squibb
Exelixis Enters Into Co-Development Agreement With Genentech
Exelixis Amends Its Collaboration Agreement With GlaxoSmithKline
Ligand Pharmaceuticals Amends Licensing Agreement With Exelixis
Exelixis Enters Into Licensing Agreement With Washington State University
Exelixis Enters Into Licensing Agreement With Bristol-Myers Squibb For XL475
Sanofi-Aventis Enters Into Licensing And Collaboration Agreement With Exelixis
Bristol-Myers Squibb Enters Into Licensing Agreement With Exelixis
Exelixis Enters Into Licensing Agreement With GlaxoSmithKline For XL880
Exelixis Enters Into Licensing Agreement With Wyeth Pharmaceuticals
Exelixis Enters Into Licensing Agreement With Symphony Evolution
Exelixis Enters Into Licensing Agreement With Helsinn Healthcare For XL119
GeneGo Enters Into Licensing Agreement With Exelixis
Exelixis Completes An Underwritten Public Offering For $190 Million
Exelixis Completes Public Offering Of $72 Million
Exelixis Completes Public Offering Of $97 Million
Exelixis Completes Public Offering Of $50 Million
Exelixis Completes Private Placement Of Senior Secured Notes For $80 Million
Taconic Farms Acquires Stake In Artemis From Exelixis
Exelixis Acquires X-Ceptor Therapeutics

List of Figures
Exelixis, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Exelixis, Inc. – Pipeline by Stage of Development, H2 2011
Exelixis, Inc. – Pipeline By Therapeutic Class, H2 2011
Exelixis, Inc. - Pipeline By Target, H2 2011
Exelixis, Inc. – Pipeline By Molecule Type, H2 2011

Customers who bought this item also bought

• Novell Sheds Light on Profitability, but Continues to Disappoint
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Cisco - A Tenuous Turnaround
• SAS
• Max India Limited - IT Sales Opportunities - 2009
• Company Profile: Quanta Computer Inc.
• Company Profile: Motech Industries Inc.
• Company Profile: AVer Information Inc.
• Company Profile: Mediatek Inc.
• MediaTek and Microsoft's Joint Foray into the Value-line Smartphone Market